Professor Edmund Chiong: Advances in PARP Inhibitor Combination Therapy and Precision Application

Professor Edmund Chiong: Advances in PARP Inhibitor Combination Therapy and Precision Application

In recent years, with the continued advancement of precision medicine, PARP inhibitors have assumed an increasingly important role in prostate cancer treatment, particularly among patients harboring homologous recombination repair (HRR) gene alterations, in whom they have demonstrated clear clinical benefits. At the same time, a range of combination strategies involving PARP inhibitors and androgen receptor pathway inhibitors (ARPIs), immunotherapy, chemotherapy, and other treatment modalities have emerged, ushering advanced prostate cancer into an era of combination therapy. However, despite the rapid accumulation of clinical evidence, questions remain regarding the optimal treatment sequence, differences in benefit across specific HRR mutation subtypes, and strategies for managing resistance in the setting of combination therapy. Further evidence is needed to clarify these issues.
2026 Pujiang Urological Oncology Academic Conference丨Professor Shudong Zhang: Surgical Treatment and Multidisciplinary Management of UTUC with Inferior Vena Cava Tumor Thrombus — From Precise Imaging Assessment to Robotic Minimally Invasive Thrombectomy and Comprehensive Care

2026 Pujiang Urological Oncology Academic Conference丨Professor Shudong Zhang: Surgical Treatment and Multidisciplinary Management of UTUC with Inferior Vena Cava Tumor Thrombus — From Precise Imaging Assessment to Robotic Minimally Invasive Thrombectomy and Comprehensive Care

The 2026 Pujiang Urological Oncology Academic Conference was held in Shanghai, bringing together experts in urological oncology from China and abroad to discuss standardized diagnosis and treatment, surgical innovation, and advances in precision medicine. Upper tract urothelial carcinoma (UTUC) complicated by inferior vena cava (IVC) tumor thrombus is relatively rare and is associated with substantially increased surgical complexity and perioperative risk. Oncology Frontier · UroStream invited Professor Shudong Zhang of Peking University Third Hospital for an interview, during which he shared his team's experience and clinical perspectives on preoperative imaging assessment and risk stratification, the application of robotic surgery, and multidisciplinary team (MDT) management throughout the treatment journey.
The 14th Lu Daopei Hematology Forum | Professor Hui Wang: Building the Foundation with Precision Diagnosis, Advancing with Intelligent Empowerment—The Clinical Value and Future Directions of Hematologic Laboratory Testing

The 14th Lu Daopei Hematology Forum | Professor Hui Wang: Building the Foundation with Precision Diagnosis, Advancing with Intelligent Empowerment—The Clinical Value and Future Directions of Hematologic Laboratory Testing

Yanzhao brings together talented individuals while remaining true to its original mission for 14 years. On August 21, 2026, the 14th Lu Daopei Hematology Forum grandly opened at Hebei Yanda Lu Daopei Hospital. Building on 14 years of academic development, this year's conference focused on cutting-edge topics including hematopoietic stem cell transplantation, cellular immunotherapy, and precision diagnosis and treatment of hematologic diseases. Experts and scholars from across the field of hematology gathered to discuss advances in the discipline, making the conference an important academic platform for promoting progress in the diagnosis and treatment of hematologic diseases in China. During the conference, Oncology Frontier – Hematology Frontier invited Professor Hui Wang of Lu Daopei Hospital for an exclusive interview. She shared her professional insights on the opportunities and challenges facing laboratory diagnosis of hematologic diseases in the era of precision medicine, the value of multidisciplinary collaboration, and the prospects for artificial intelligence applications.
The 14th Lu Daopei Hematology Forum | Peihua Lu: Fourteen Years of Staying True to the Mission and Embarking on a New Journey—The Value and Future of an Academic Platform for Hematology

The 14th Lu Daopei Hematology Forum | Peihua Lu: Fourteen Years of Staying True to the Mission and Embarking on a New Journey—The Value and Future of an Academic Platform for Hematology

Yanzhao brings together talented individuals while remaining true to its original mission for 14 years. On August 21, 2026, the the 14th Lu Daopei Hematology Forum grandly opened at Hebei Yanda Lu Daopei Hospital. Building on 14 years of academic development, this year's conference focused on cutting-edge topics including hematopoietic stem cell transplantation, cellular immunotherapy, and precision diagnosis and treatment of hematologic diseases. Experts and scholars from across the field of hematology gathered to discuss advances in the discipline, making the conference an important academic platform for promoting progress in the diagnosis and treatment of hematologic diseases in China. During the conference, Oncology Frontier – Hematology Frontier invited Professor Peihua Lu of Lu Daopei Hospital for an exclusive interview. She shared her insights into the highlights of this year's conference, the value of the academic platform, and the role of multidisciplinary collaboration and research in advancing clinical practice.
The 14th Lu Daopei Hematology Forum | Dongchu Wang: Unlocking the Predictive Value of Cytokines and Optimizing the Entire Treatment Pathway—Research and Prospects of CD7 CAR-T as a Bridge to Transplantation

The 14th Lu Daopei Hematology Forum | Dongchu Wang: Unlocking the Predictive Value of Cytokines and Optimizing the Entire Treatment Pathway—Research and Prospects of CD7 CAR-T as a Bridge to Transplantation

Yanzhao brings together talented individuals while remaining true to its original mission for 14 years. On August 21, 2026, the 14th Lu Daopei Hematology Forum grandly opened at Hebei Yanda Lu Daopei Hospital. Building on 14 years of academic development, this year's conference focused on cutting-edge topics including hematopoietic stem cell transplantation, cellular immunotherapy, and precision diagnosis and treatment of hematologic diseases. Experts and scholars from across the field of hematology gathered to discuss advances in the discipline, making the conference an important academic platform for promoting progress in the diagnosis and treatment of hematologic diseases in China. During the conference, Oncology Frontier – Hematology Frontier invited Dongchu Wang of Lu Daopei Hospital for an exclusive interview. He shared his insights into the current landscape of CD7 CAR-T therapy for T-cell malignancies, research on the association between cytokine levels and graft-versus-host disease (GVHD) following bridge-to-transplantation therapy, and future directions for combining CAR-T therapy with transplantation.
The 14th Lu Daopei Hematology Forum | Dr. Shu Yan: Stratified Prevention and Control, Comprehensive Management—Strategies for the Diagnosis and Treatment of Invasive Fungal Disease After Hematopoietic Stem Cell Transplantation

The 14th Lu Daopei Hematology Forum | Dr. Shu Yan: Stratified Prevention and Control, Comprehensive Management—Strategies for the Diagnosis and Treatment of Invasive Fungal Disease After Hematopoietic Stem Cell Transplantation

Yanzhao brings together talented individuals while remaining true to its original mission for 14 years. On August 21, 2026, the 14th Lu Daopei Hematology Forum grandly opened at Hebei Yanda Lu Daopei Hospital. Building on 14 years of academic development, this year's conference focused on cutting-edge topics including hematopoietic stem cell transplantation, cellular immunotherapy, and precision diagnosis and treatment of hematologic diseases. Experts and scholars from across the field of hematology gathered to discuss advances in the discipline, making the conference an important academic platform for promoting progress in the diagnosis and treatment of hematologic diseases in China. During the conference, Oncology Frontier – Hematology Frontier invited Dr. Shu Yan of Hebei Yanda Lu Daopei Hospital for an exclusive interview. He shared his professional insights on the epidemiological characteristics of invasive fungal disease (IFD) after hematopoietic stem cell transplantation, comprehensive management pathways, and treatment optimization strategies.
The 14th Lu Daopei Hematology Forum | Dr. Jiujiang He: Establishing Venetoclax as a Cornerstone and Exploring Standardized Practice—Clinical Applications and Future Perspectives of Venetoclax in AML

The 14th Lu Daopei Hematology Forum | Dr. Jiujiang He: Establishing Venetoclax as a Cornerstone and Exploring Standardized Practice—Clinical Applications and Future Perspectives of Venetoclax in AML

Yanzhao brings together talented individuals while remaining true to its original mission for 14 years. On August 21, 2026, the 14th Lu Daopei Hematology Forum grandly opened at Hebei Yanda Lu Daopei Hospital. Building on 14 years of academic development, this year's conference focused on cutting-edge topics including hematopoietic stem cell transplantation, cellular immunotherapy, and precision diagnosis and treatment of hematologic diseases. Experts and scholars from across the field of hematology gathered to discuss advances in the discipline, making the conference an important academic platform for promoting progress in the diagnosis and treatment of hematologic diseases in China. During the conference, Oncology Frontier – Hematology Frontier invited Dr. Jiujiang He of Hebei Yanda Lu Daopei Hospital for an exclusive interview. He shared his professional insights on the therapeutic role of venetoclax in acute myeloid leukemia (AML), challenges in real-world clinical practice, and future directions, providing perspectives and references for the standardized diagnosis and treatment of AML.
the 14th Lu Daopei Hematology Forum丨Dr. Xiaosu Zhou: Decoding the “Genetic Code” of Atypical APL — Far Greater Complexity and Heterogeneity Than Expected

the 14th Lu Daopei Hematology Forum丨Dr. Xiaosu Zhou: Decoding the “Genetic Code” of Atypical APL — Far Greater Complexity and Heterogeneity Than Expected

On August 21, 2026, the 14th Lu Daopei Hematology Forum was successfully held at the new campus of Hebei Yanda Lu Daopei Hospital. After 14 years of continuous development, the Lu Daopei Hematology Academic Conference has become an influential platform for academic exchange in the field of hematology in China, witnessing the evolution of hematologic disease diagnosis and treatment from accumulated clinical experience toward evidence-based innovation. During the conference, Oncology Frontier – Hematology Frontier invited Dr. Xiaosu Zhou from the Beijing Lu Daopei Institute of Hematology to share the latest research findings on atypical acute promyelocytic leukemia (APL), focusing on its fusion gene landscape, underlying pathogenesis, and prospects for clinical translation.
Frontiers in Immunology | Germline Genetic Susceptibility Genes May Enable More Precise Donor Selection for Hematopoietic Stem Cell Transplantation — Clinical Insights from a 558-Patient Transplant Cohort

Frontiers in Immunology | Germline Genetic Susceptibility Genes May Enable More Precise Donor Selection for Hematopoietic Stem Cell Transplantation — Clinical Insights from a 558-Patient Transplant Cohort

As precision medicine continues to advance in hematologic malignancies, the clinical value of germline genetic factors is gradually extending beyond disease-risk assessment to influence treatment decision-making. For patients undergoing hematopoietic stem cell transplantation (HSCT), donor selection has traditionally focused on factors such as HLA matching, donor–recipient relationship, donor age, and overall health status. However, an increasingly important question is: Could the germline genetic backgrounds shared by or differing between donors and recipients also affect post-transplant disease control, infection risk, and long-term survival?
Nature Reviews | The International Chinese Young Scholars Alliance for the Study of the Liver Facilitates Global Collaboration

Nature Reviews | The International Chinese Young Scholars Alliance for the Study of the Liver Facilitates Global Collaboration

On August 25, 2026, Nature Reviews Gastroenterology & Hepatology (IF 57.5) published online a commentary titled "The International Chinese Young Scholars Alliance for the Study of the Liver: facilitating global collaboration," jointly completed by Xiaolong Qi (Zhongda Hospital Southeast University, China), Wenhao Li (Royal London Hospital, UK), Zhujun Cao (European Foundation for the Study of Chronic Liver Failure / Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China), Yee Hui Yeo (Cedars-Sinai Medical Center, Los Angeles, USA), Ying Shang (Karolinska Institutet, Solna, Sweden), and Kaina Chen (Singapore General Hospital, Singapore).